BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19212605)

  • 1. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
    Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
    Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
    Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
    J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence].
    Lapa P; Silva R; Saraiva T; Figueiredo A; Ferreira R; Costa G; Lima JP
    Acta Med Port; 2016 Mar; 29(3):182-92. PubMed ID: 27285094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
    Buchegger F; Garibotto V; Zilli T; Allainmat L; Jorcano S; Vees H; Rager O; Steiner C; Zaidi H; Seimbille Y; Ratib O; Miralbell R
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
    Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
    Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
    Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
    Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
    Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
    Cimitan M; Bortolus R; Morassut S; Canzonieri V; Garbeglio A; Baresic T; Borsatti E; Drigo A; Trovò MG
    Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1387-98. PubMed ID: 16865395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence.
    El Kabbaj O; Robin P; Bourhis D; Dissaux G; Rosenfelder N; Valeri A; Fournier G; Salaun PY; Pradier O; Malhaire JP; Abgral R; Schick U
    Acta Oncol; 2018 Mar; 57(3):375-381. PubMed ID: 28984165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
    Tong AK; Zhang ZX; Zaheer S; Yan XS
    Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.
    Igerc I; Kohlfürst S; Gallowitsch HJ; Matschnig S; Kresnik E; Gomez-Segovia I; Lind P
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):976-83. PubMed ID: 18188560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
    Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
    Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.